Please enable JavaScript to continue using this application.

Compare $AVXL vs $OTLK | Chartloom

Compare

$AVXL vs $OTLK

Anavex Life Sciences Corp · Outlook Therapeutics Inc

AVXL

Anavex Life Sciences Corp

OTLK

Outlook Therapeutics Inc

Compare $AVXL vs $OTLK

Comparing Anavex Life Sciences Corp and Outlook Therapeutics Inc

AVXLAnavex Life Sciences Corp

OTLKOutlook Therapeutics Inc

AVXLAnavex Life Sciences Corp

Market cap

$138M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-59.5%

52W performance

-84.9%

FCF yield

-21.2%

OTLKOutlook Therapeutics Inc

Market cap

$112M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

3.58x

Rev growth (TTM)

-171.2%

YTD performance

-9.3%

52W performance

-52.5%

FCF yield

-50.1%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AVXL

OTLK

Detailed metrics comparison

AVXL

Anavex Life Sciences Corp

OTLK

Outlook Therapeutics Inc

Market Cap

AVXL$138M

OTLK$112M

Enterprise Value

AVXL$20M

OTLK$119M

Price

AVXL$1.49

OTLK$0.60

P/E Ratio

AVXLN/A

OTLKN/A

P/S Ratio

AVXL0.00x

OTLK0.00x

EV/Sales

AVXL0.00x

OTLK1,109.27x

EV/EBITDA

AVXL0.00x

OTLK0.00x

P/B Ratio

AVXL1.50x

OTLK13.76x

P/FCF Ratio

AVXLN/A

OTLKN/A

EV/FCF

AVXL-0.67x

OTLK-2.12x

PEG Ratio

AVXLN/A

OTLKN/A

Forward P/E (NTM)

AVXLN/A

OTLKN/A

Forward P/S (NTM)

AVXLN/A

OTLK3.58x

Revenue (TTM)

AVXL$0

OTLK$-1M

Revenue Growth (YoY)

AVXLN/A

OTLK-171.2%

Forward Rev Growth

AVXL377.5%

OTLK26.4%

Gross Margin (TTM)

AVXL0.0%

OTLK203.8%

Operating Margin (TTM)

AVXL0.0%

OTLK0.0%

EBITDA Margin (TTM)

AVXL0.0%

OTLK5181.7%

Net Margin (TTM)

AVXL0.0%

OTLK5703.4%

FCF Margin (TTM)

AVXLN/A

OTLKN/A

Net Income (TTM)

AVXL$-13M

OTLK$-61M

FCF (TTM)

AVXL$-29M

OTLK$-56M

EPS (TTM)

AVXL-$0.14

OTLK-$0.45

ROE (TTM)

AVXL-1143.0%

OTLK-41551.0%

ROA (TTM)

AVXL-1072.0%

OTLK-28798.0%

ROIC (TTM)

AVXL-1143.0%

OTLK-16327.0%

Cash

AVXL$118M

OTLK$11M

Debt

AVXL$0

OTLK$18M

Net Cash/Debt

AVXL$118M

OTLK$-7M

Current Ratio (TTM)

AVXL15.62x

OTLK0.81x

Quick Ratio (TTM)

AVXL15.51x

OTLK0.45x

Debt/Equity (TTM)

AVXL0.00x

OTLK3.04x

Debt/Assets (TTM)

AVXL0.0%

OTLK0.0%

Interest Coverage (TTM)

AVXLN/A

OTLKN/A

Net Debt/EBITDA (TTM)

AVXL0.00x

OTLK0.00x

Beta

AVXL1.20

OTLK0.64

52W Performance

AVXL-84.9%

OTLK-52.5%

YTD Performance

AVXL-59.5%

OTLK-9.3%

% from 52W High

AVXL-85.0%

OTLK-76.4%

% from 52W Low

AVXL3.5%

OTLK271.8%

Asset Turnover (TTM)

AVXL0.00x

OTLK0.01x

FCF Yield (TTM)

AVXL-21.2%

OTLK-50.1%

Earnings Yield (TTM)

AVXL-9.4%

OTLK-54.6%

Dividend Yield (TTM)

AVXLN/A

OTLKN/A

Rule of 40

AVXL0.0

OTLK5,010.5

EV/GP/RG

AVXLN/A

OTLKN/A

Ticker research

View AVXL research View OTLK research

Metric	AVXL Anavex Life Sciences Corp	OTLK Outlook Therapeutics Inc
Market & Valuation
Market Cap	$138M	$112M
Enterprise Value	$20M	$119M
Price	$1.49	$0.60
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	1,109.27x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.50x	13.76x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.67x	-2.12x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	3.58x
Revenue & Growth
Revenue (TTM)	$0	$-1M
Revenue Growth (YoY)	N/A	-171.2%
Forward Rev Growth	377.5%	26.4%
Profitability
Gross Margin (TTM)	0.0%	203.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	5181.7%
Net Margin (TTM)	0.0%	5703.4%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-13M	$-61M
FCF (TTM)	$-29M	$-56M
EPS (TTM)	-$0.14	-$0.45
ROE (TTM)	-1143.0%	-41551.0%
ROA (TTM)	-1072.0%	-28798.0%
ROIC (TTM)	-1143.0%	-16327.0%
Financial Health
Cash	$118M	$11M
Debt	$0	$18M
Net Cash/Debt	$118M	$-7M
Current Ratio (TTM)	15.62x	0.81x
Quick Ratio (TTM)	15.51x	0.45x
Debt/Equity (TTM)	0.00x	3.04x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.20	0.64
52W Performance	-84.9%	-52.5%
YTD Performance	-59.5%	-9.3%
% from 52W High	-85.0%	-76.4%
% from 52W Low	3.5%	271.8%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.01x
FCF Yield (TTM)	-21.2%	-50.1%
Earnings Yield (TTM)	-9.4%	-54.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	5,010.5
EV/GP/RG	N/A	N/A
Ticker research	View AVXL research	View OTLK research

Valuation

P/S Ratio

AVXL

0.00x

OTLK

0.00x

EV/FCF

OTLK

-2.12x

AVXL

-0.67x

Growth & revenue

Revenue Growth TTM

OTLK

-171.2%

Forward Revenue Growth

AVXL

377.5%

OTLK

26.4%

Profitability & performance

Gross Margin

OTLK

203.8%

AVXL

0.0%

ROE

AVXL

-1143.0%

OTLK

-41551.0%

FCF Yield %

AVXL

-21.2%

OTLK

-50.1%

52-Week Performance

OTLK

-52.5%

AVXL

-84.9%

Detailed metrics comparison

AVXL

Anavex Life Sciences Corp

OTLK

Outlook Therapeutics Inc

Market Cap

AVXL$138M

OTLK$112M

Enterprise Value

AVXL$20M

OTLK$119M

Price

AVXL$1.49

OTLK$0.60

P/E Ratio

AVXLN/A

OTLKN/A

P/S Ratio

AVXL0.00x

OTLK0.00x

EV/Sales

AVXL0.00x

OTLK1,109.27x

EV/EBITDA

AVXL0.00x

OTLK0.00x

P/B Ratio

AVXL1.50x

OTLK13.76x

P/FCF Ratio

AVXLN/A

OTLKN/A

EV/FCF

AVXL-0.67x

OTLK-2.12x

PEG Ratio

AVXLN/A

OTLKN/A

Forward P/E (NTM)

AVXLN/A

OTLKN/A

Forward P/S (NTM)

AVXLN/A

OTLK3.58x

Revenue (TTM)

AVXL$0

OTLK$-1M

Revenue Growth (YoY)

AVXLN/A

OTLK-171.2%

Forward Rev Growth

AVXL377.5%

OTLK26.4%

Gross Margin (TTM)

AVXL0.0%

OTLK203.8%

Operating Margin (TTM)

AVXL0.0%

OTLK0.0%

EBITDA Margin (TTM)

AVXL0.0%

OTLK5181.7%

Net Margin (TTM)

AVXL0.0%

OTLK5703.4%

FCF Margin (TTM)

AVXLN/A

OTLKN/A

Net Income (TTM)

AVXL$-13M

OTLK$-61M

FCF (TTM)

AVXL$-29M

OTLK$-56M

EPS (TTM)

AVXL-$0.14

OTLK-$0.45

ROE (TTM)

AVXL-1143.0%

OTLK-41551.0%

ROA (TTM)

AVXL-1072.0%

OTLK-28798.0%

ROIC (TTM)

AVXL-1143.0%

OTLK-16327.0%

Cash

AVXL$118M

OTLK$11M

Debt

AVXL$0

OTLK$18M

Net Cash/Debt

AVXL$118M

OTLK$-7M

Current Ratio (TTM)

AVXL15.62x

OTLK0.81x

Quick Ratio (TTM)

AVXL15.51x

OTLK0.45x

Debt/Equity (TTM)

AVXL0.00x

OTLK3.04x

Debt/Assets (TTM)

AVXL0.0%

OTLK0.0%

Interest Coverage (TTM)

AVXLN/A

OTLKN/A

Net Debt/EBITDA (TTM)

AVXL0.00x

OTLK0.00x

Beta

AVXL1.20

OTLK0.64

52W Performance

AVXL-84.9%

OTLK-52.5%

YTD Performance

AVXL-59.5%

OTLK-9.3%

% from 52W High

AVXL-85.0%

OTLK-76.4%

% from 52W Low

AVXL3.5%

OTLK271.8%

Asset Turnover (TTM)

AVXL0.00x

OTLK0.01x

FCF Yield (TTM)

AVXL-21.2%

OTLK-50.1%

Earnings Yield (TTM)

AVXL-9.4%

OTLK-54.6%

Dividend Yield (TTM)

AVXLN/A

OTLKN/A

Rule of 40

AVXL0.0

OTLK5,010.5

EV/GP/RG

AVXLN/A

OTLKN/A

Ticker research

View AVXL research View OTLK research

Metric	AVXL Anavex Life Sciences Corp	OTLK Outlook Therapeutics Inc
Market & Valuation
Market Cap	$138M	$112M
Enterprise Value	$20M	$119M
Price	$1.49	$0.60
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	1,109.27x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.50x	13.76x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.67x	-2.12x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	3.58x
Revenue & Growth
Revenue (TTM)	$0	$-1M
Revenue Growth (YoY)	N/A	-171.2%
Forward Rev Growth	377.5%	26.4%
Profitability
Gross Margin (TTM)	0.0%	203.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	5181.7%
Net Margin (TTM)	0.0%	5703.4%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-13M	$-61M
FCF (TTM)	$-29M	$-56M
EPS (TTM)	-$0.14	-$0.45
ROE (TTM)	-1143.0%	-41551.0%
ROA (TTM)	-1072.0%	-28798.0%
ROIC (TTM)	-1143.0%	-16327.0%
Financial Health
Cash	$118M	$11M
Debt	$0	$18M
Net Cash/Debt	$118M	$-7M
Current Ratio (TTM)	15.62x	0.81x
Quick Ratio (TTM)	15.51x	0.45x
Debt/Equity (TTM)	0.00x	3.04x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.20	0.64
52W Performance	-84.9%	-52.5%
YTD Performance	-59.5%	-9.3%
% from 52W High	-85.0%	-76.4%
% from 52W Low	3.5%	271.8%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.01x
FCF Yield (TTM)	-21.2%	-50.1%
Earnings Yield (TTM)	-9.4%	-54.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	5,010.5
EV/GP/RG	N/A	N/A
Ticker research	View AVXL research	View OTLK research